

Recent Presentations by the Center for the Treatment and Study of Neuropsychiatric Disorders

Marotta, Rocco F., “Onset of Illness: The Changing Face of Severe Psychiatric Illness in the Early 21st Century.” Oral presentation at the Center for the Treatment and Study of Neuropsychiatric Disorders, Silver Hill Hospital, Grace Farms Conference, The Long Course of Care: Interfaces of Multiple Systems and Stakeholders, December 2024.

Marotta, Rocco F., “Cannabis and Stimulants: Unraveling Psychosis and Novel Clinical Presentation.” Oral presentation at The Dorm Webinar, November 2024.

Marotta, Rocco F., Lisa Mann, Katharine Cutts Dougherty, et. al. “Expanding Directions in the Treatment of Serious Mental Illness: Beyond the Double Blind,” Paper presented at The Center for the Treatment and Study of Neuropsychiatric Disorders Colloquium, Rome, Italy, April 2024.

Marotta, Rocco F., Irene Bihl, Meriwether Brown, et al. “Building a Continuum of Care for Treatment-Resistant Schizophrenia Spectrum Disorders.” Poster presented at the Congress of the Schizophrenia International Research Society, April 2024.

Walker, Sophia, Katharine Cutts Dougherty, Howard Weiner, et al. “Complex Seizure Disorder Symptoms Manifesting in Treatment-Resistant Schizophrenia Spectrum Disorders in Young Adults with Prior Cannabis Use: A Clinical Overview.” Poster presented at the Congress of the Schizophrenia International Research Society, April 2024.

Marotta, Rocco F., “Treatment-Resistant Schizophrenia in Young Adulthood: Treatment Strategies and Common Barriers,” Virtual Continuing Education Presentation at The Dorm, November 2023.

Marotta, Rocco F., “Neuropsychiatric Manifestations of COVID Infections: Clinical Presentations & Possible Underlying Pathophysiology.” Oral presentation at Silver Hill Hospital Virtual Grand Rounds, June 2023.

Marotta, Rocco F., Katharine Cutts Dougherty, Meriwether Brown, et al. “Maximizing Recovery from Schizophrenia Spectrum Disorders in a Hospital/Residential Setting: Clozapine, Oxytocin, Psychosocial and Family Programs.” Poster presented at the American Psychiatric Association Annual Meeting, May 2023.

Rocco F. Marotta, Katharine Cutts Dougherty, Frank Buono, et al. “Long- Term Effects of Clozapine and Oxytocin on Functional Recovery and Sobriety Maintenance in Treatment Resistant Schizophrenia.” Oral presentation to the Congress of the Schizophrenia International Research Society, April 2022.

Marotta, Rocco F., “Addressing the Common Course of Schizophrenia: Effect of Clozapine and Sublingual Oxytocin on Substance Use Relapse and Long-Term Life Trajectories.” Paper presented to the American Academy of Addiction Psychiatry Annual Meeting and Scientific Symposium, December 2021.

Marotta, Rocco F., “Oxytocin as an Augmentation to the Treatment of Schizophrenia with Clozapine: Improvement in Negative Symptoms and Life Paths.” Oral presentation to New York-Presbyterian Westchester Hospital, May 2021.

Rocco F. Marotta, “Oxytocin as an Augmentation to the Treatment of Schizophrenia with Clozapine: Improvement in Negative Symptoms and Life Paths.” Oral presentation at Silver Hill Hospital Grand Rounds, March 2021.

Marotta, Rocco F., “Oxytocin as an Augmentation to the Treatment of Schizophrenia with Clozapine: Improvement in Negative Symptoms and Life Paths.” Oral presentation at Institute of Living, Hartford Hospital Grand Rounds, January 2021.

Marotta, Rocco F., Katharine Cutts Dougherty, David Rowe, et al. “Can Augmented Sublingual Oxytocin Decrease Negative Symptoms within Treatment Resistant Schizophrenic Populations: A Pilot Study.” Poster presented at the Congress of the Schizophrenia International Research Society, April 2020.

Marotta, Rocco F., “Creative Psychiatry: Learn about the Benefits of Oxytocin for Psychosis.” Interview by Virgil Stucker. Mental Horizons, S3EP3, <https://podcasts.apple.com/us/podcast/s3ep3-creative-psychiatry-with-rocco-marotta-learn/id1476557069?i=1000492480387>

Dr. Marotta and his team conduct a monthly Neuropsychiatric Case Conference Program for Silver Hill Hospital clinicians. This program increases clinical understanding of treating patients with persistent psychotic illness, especially those who have undergone multiple unsuccessful interventions.

###